Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is poised for future success with a solid cash runway through 2029 and promising clinical assets targeting major depressive disorders and schizophrenia. The company has demonstrated resilience in addressing eligibility and compliance issues with key pipeline updates, positioning it for potential regulatory filings as early as 2028. With a differentiated approach to identifying best responders and a strong focus on trial-quality controls, ANRO has the potential to make a significant impact in the field of personalized psychiatry.

Bears say

Alto Neuroscience is currently a clinical-stage biopharmaceutical company with a focus on developing personalized treatments utilizing biomarkers for CNS disorders. However, the company's pipeline products have shown mixed results in clinical trials and their approach to precision medicine is still unproven. In addition, the company relies heavily on third parties for drug supply and manufacturing, as well as conducting preclinical studies and clinical trials, which poses risks to the company's success. The company also faces significant financial risks and may need to raise additional capital which could result in share dilution for shareholders. Overall, the company's current status as a development stage company and its unproven approach to precision medicine make for a negative outlook on its stock.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.